Spots Global Cancer Trial Database for AZD1152 in Diffuse Large B-cell Lymphoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: AZD1152 in Diffuse Large B-cell Lymphoma
Official Title: A Phase 2 Trial of AZD1152 in Relapsed/Refractory Diffuse Large B-cell Lymphoma
Study ID: NCT01354392
Conditions
Interventions
Study Description
Brief Summary: Diffuse large B-cell lymphoma is the commonest type of aggressive non-Hodgkin's lymphoma, a type of cancer of a cell called a lymphocyte which makes up part of the immune system. Although most patients are cured with chemotherapy used as initial treatment, about 20-30% of patients still experience relapse. Curing relapsed disease is much less successful, even with the use of high doses of chemotherapy and stem cell transplant. There is then an urgent need for effective, new agents to treat patients with diffuse large B-cell lymphoma who have relapsed or who have developed resistance to other forms of chemotherapy. This trial is using a drug called AZD1152 which interferes with the ability of a cancer cell to divide and grow. It has been used before in patients with other types of cancer, but never before in lymphoma patients. Responses in other cancers have been seen, particularly in leukaemia which is a disease related to lymphoma. The investigators are planning to use this agent in 15 patients with diffuse large B-cell lymphoma in which potentially curative treatments have failed. The main aim is to see whether the drug shows any activity in this type of lymphoma. This will be mainly assessed using CT and PET scans. The investigators are also investigating how well a blood test can predict both the response to the drug and the toxicity of the drug - this is called a biomarker study and forms part of the clinical trial. The other main aim of the study is to assess the toxicity of the treatment. Previous studies in humans suggest the drug is reasonably well tolerated, although side effects such as stomatitis (soreness of the mouth) and suppression of the bone marrow (leading to risk of infection and bleeding) have been seen.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Christie NHS Foundation Trust (Christie Hospital), Machester, Lancashire, United Kingdom
Oxford Radcliffe NHS Trust (Cancer & Haematology Centre, Churchill Hospital), Oxford, Oxfordshire, United Kingdom
Contact Details
Name: Chris Hatton, MRCPath FRCPath(UK) MRCP FRCP
Affiliation: Oxford Radcliffe NHS Trust & University of Oxford
Role: STUDY_DIRECTOR
Name: John A Radford, MB, ChB, MRCP, MD, FRCP
Affiliation: University of Manchester, Christie NHS Foundation Trust
Role: PRINCIPAL_INVESTIGATOR
Name: Graham P Collins, MBBS, MRCP(UK), FRCPath
Affiliation: Oxford Radcliffe NHS Trust, University of Oxford
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
